Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Aldeyra Therapeutics Inc (Aldeyra Therapeutics) is a biotechnology company that discovers and develops therapies for treating immune-mediated and metabolic diseases. The company’s pipeline includes Reproxalap for treating Dry Eye Disease and Allergic Conjunctivitis; ADX-629 for moderate alcoholic hepatitis, sjögren-larsson syndrome, ADX-248 for Atopic Dermatitis, ADX-743 for obesity and hypertriglyceridemia, ADX-631 and ADX-246 for dry age-related macular degeneration and geographic atrophy and ADX-2191 for retinitis pigmentosa. The company also utilizes the RASP (reactive aldehyde species) modulator platform. It operates in Germany and the US. Aldeyra Therapeutics is headquartered in Lexington, Massachusetts, the US.
Headquarters
United States of America
Address
Suite 320, 131 Hartwell Avenue, Lexington, Massachusetts, 02421
Website
www.aldeyra.com
Telephone
1 781 7614904
No of Employees
8
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
ALDX (NASD)
EPS
XYZ
Net Income (2024)
XYZ
39.4%
(2024 vs 2023)
Market Cap*
$146.6M
* As of and is in US$
Products and Services
| Products |
|---|
| Pipeline |
| Reproxalap: Dry Eye Disease, Allergic Conjunctivitis |
| ADX-629: Moderate Alcoholic Hepatitis, Sjögren-Larsson Syndrome |
| XYZ |
| XYZ |
| XYZ |
Competitor Comparison
| Key Parameters | Aldeyra Therapeutics Inc | Johnson & Johnson | Eli Lilly and Co | Merck & Co Inc | Pfizer Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Lexington | New Brunswick | Indianapolis | Rahway | New York City |
| State/Province | Massachusetts | New Jersey | Indiana | New Jersey | New York |
| No. of Employees | 8 | 138,200 | 50,605 | 75,000 | 75,000 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Richard H. Douglas Ph.D. | Chairman | Executive Board | 2016 | 72 |
| Todd C. Brady, M.D., Ph.D. | President; Director; Chief Executive Officer | Executive Board | 2012 | 53 |
| Bill Cavanagh | Vice President - Clinical Operations | Senior Management | 2023 | - |
| Stephen G. Machatha, Ph.D. | Chief Development Officer | Senior Management | 2021 | 48 |
| Nancy Miller-Rich | Director | Non Executive Board | 2020 | 66 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer